Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Rises By 13.5%

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, a growth of 13.5% from the December 15th total of 22,940,000 shares. Based on an average trading volume of 2,170,000 shares, the short-interest ratio is presently 12.0 days.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its position in Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock valued at $35,000 after purchasing an additional 18,053 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Lineage Cell Therapeutics during the 2nd quarter valued at about $61,000. GSA Capital Partners LLP bought a new stake in Lineage Cell Therapeutics in the 3rd quarter worth approximately $84,000. Rhumbline Advisers boosted its stake in Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock worth $132,000 after buying an additional 17,411 shares in the last quarter. Finally, Barclays PLC grew its position in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company's stock valued at $192,000 after acquiring an additional 159,924 shares during the last quarter. Institutional investors own 62.47% of the company's stock.

Analyst Ratings Changes

LCTX has been the topic of several recent research reports. Maxim Group cut their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. D. Boral Capital restated a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Finally, HC Wainwright raised their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $4.80.

Lineage Cell Therapeutics Stock Performance

Lineage Cell Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $0.59. The stock had a trading volume of 714,071 shares, compared to its average volume of 2,333,271. The stock has a market capitalization of $129.47 million, a P/E ratio of -4.90 and a beta of 1.18. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.